Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bilal Ansari (NPI 1386648749)

Field	Value
Entity Type	Individual
Organization	Bilal Ansari
Address	5340 Holy Cross Pkwy
City	Mishawaka
State	IN
ZIP	46545
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 13, 2005

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

Practice mix is consistent with a medical oncology infusion practice: the highest-revenue line items are oncology biologics and chemotherapy administration codes, with J9271 (pembrolizumab) and J9144 (daratumumab) among the largest single-code revenue drivers and multiple chemotherapy administration and add-on codes (96413, 96417, 96401, 96365) appearing in the top 25. These codes and their dollar amounts point to a service model centered on outpatient infusion of high-cost anticancer agents rather than procedural surgery or non-oncologic specialties.

Revenue concentration is high: the precomputed top-3 share shows the provider’s top three Medicare codes account for 65.7% of total Medicare revenue. Those top three codes are J9271 ($455.8K, 28.3%), J9144 ($366.3K, 22.7%), and 99214 ($237.9K, 14.8%), indicating that a small set of drug and E/M codes drive the bulk of the $1.7M Medicare revenue.

This provider is effectively single-payer at present: total Medicare revenue is $1.7M while there is no Medicaid billing on file. The absence of Medicaid claims means payer-concentration risk is material and reimbursement sensitivity will be tied primarily to Medicare coverage and pricing for oncology drugs and clinic visits.

Competitive standing on major oncology drugs is modest to typical: J9271 ranks #1102 of 1841 providers (39th percentile) and J9144 ranks #213 of 615 providers (64th percentile), both described as "typical, unremarkable volume" in the national peer context. These rankings suggest the provider is not a dominant national supplier of these agents despite substantial absolute dollars from them.

Office visit volume is an outlier: 99214 appears with 2.7K claims, $237.9K revenue and is labeled an "extreme outlier, far above typical national volume" at the national level. This unusually high volume of moderate-complexity established-patient visits suggests either a large established patient panel, high visit frequency, or a billing profile concentrated on higher-level E/M encounters compared with peers.

Imaging and diagnostic services appear as meaningful ancillary revenue: 78815 (PET/CT) contributes $106.1K (6.6% of Medicare revenue) and CT codes such as 74177 ($41.3K) and 71260 ($17.3K) are present, with 71260 noted as "notably above typical national volume." The mix indicates regular use or ordering of advanced imaging consistent with active oncology management and staging/follow-up workflows.

High claim counts for low-dollar drug codes point to frequent, routine supportive treatments or supply-level billing: J0881 shows 24.4K claims for $48.8K revenue (3.0% of Medicare revenue) and 96375 has 801 claims for $8.8K, both described as "typical, unremarkable volume." These patterns are consistent with frequent administration of low-dollar injectable agents or recurring supportive care items that create volume but not large revenue per claim.

Tenure and scale: the provider’s NPI was enumerated on 2005-06-13 (~21 years ago), indicating a long-established billing history. Combined with $1.7M lifetime Medicare revenue and the coding profile above, the provider presents as an experienced, mid-scale oncology outpatient practice that is nationally modest on drug volumes but highly active in E/M encounters.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

55 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	10,600	$40	$455.8K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	9,900	$40	$366.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	2,700	$90	$237.9K
J0897	Injection, denosumab, 1 mg	7,080	$20	$127.4K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	90	$1,140	$106.1K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	24,380	$1	$48.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$90	$42.5K
74177	The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs.	250	$170	$41.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	640	$60	$39.7K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	340	$90	$29.2K

Showing 1–10 of 55

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 55 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Bilal Ansari — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

55 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	13	20	11,200	$40	$631.7K
J9144	2	10	12,960	$40	$484.3K
J0897	33	220	2,730	$20	$74.9K
J0881	5	10	20,080	$1	$47.4K
78815	43	140	60	$300	$26.6K
Q5108	2	10	310	$80	$24.6K
J9217	33	90	150	$130	$23K
96413	11	120	140	$90	$19.1K
99214	2	10,540	110	$80	$15.5K
J3490	23	40	50	$180	$12.8K

Showing 1–10 of 55

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bilal Ansari, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Beacon Medical Group, Inc.	IN	Urgent Care Clinic/Center	$0	$7.2M
Woodlawn Hospital	IN	Critical Access Hospital	$0	$5.3M
Beacon Medical Group, Inc.	IN	Family Medicine Physician	$0	$4.7M
Michiana Hematology-oncology P C	IN	Medical Oncology Physician	$0	$3M
Mohamed Farhat	IN	Medical Oncology Physician	$2.2M	$0
Eduardo Braun	IN	Medical Oncology Physician	$1.8M	$0
Rashid Khan	IN	Medical Oncology Physician	$1.5M	$0
Brion Shin	TN	Radiation Oncology Physician	$1.5M	$0
Binh Tran	IN	Radiation Oncology Physician	$1M	$0
Sayuri Cheruvu	IN	Medical Oncology Physician	$934.1K	$0

Nearby Providers

Other providers in the same ZIP code as Bilal Ansari, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Saint Joseph Regional Medical Center-south Bend Campus, Inc.	IN	General Acute Care Hospital	$0	$18.7M
Toxusa Labs LLC	IN	Clinical Medical Laboratory	$1.3M	$9.6M
Pic Indiana PC	IN	Urgent Care Clinic/Center	$0	$10.7M
Radiology, Inc	IN	Diagnostic Radiology Physician	$0	$6.8M
Miracle Lane Family Dentistry P.C.	IN	Dental Clinic/Center	$0	$5.1M
Michiana Eye Center LLC	IN	Ophthalmology Physician	$0	$5M
Saint Joseph Regional Medical Center-south Bend Campus, Inc.	IN	Family Medicine Physician	$0	$4.8M
Northern Indiana Interim Healthcare Company LLC	IN	Home Health Agency	$0	$4.5M
Del Pilar Medical & Urgent Care PC	IN	Geriatric Medicine (Family Medicine) Physician	$0	$3.6M
Linda Monroe	IN	Clinical Psychologist	$15.4K	$2.9M

Bilal Ansari — Billing Profile & Reimbursement Data

Sign up for Bilal Ansari — Billing Profile & Reimbursement Data policy alerts

Bilal Ansari — Billing Profile & Reimbursement Data

Sign up for Bilal Ansari — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References